IQVIA HOLDINGS INC.
IQVIQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.
Drugs in Pipeline
27
Phase 3 Programs
11
Upcoming Catalysts
4
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
4 upcoming, 0 past
GSK3196165 (Otilimab)
Arthritis, Rheumatoid
GSK3511294 (Depemokimab)
Asthma
Humira 40 MG in Prefilled Syringe
Moderate Chronic Plaque Psoriasis
Tapinarof
Plaque Psoriasis
Olokizumab 64 mg SC q4w
Rheumatoid Arthritis
Levodopa-Carbidopa Intestinal Gel (LCIG)
Advanced Parkinson's Disease
Tofacitinib 5 mg
Arthritis, Rheumatoid
Recombinant human alpha galactosidase A (agalsidase beta)
Fabry Disease
Benralizumab
Severe Uncontrolled Asthma
Etripamil NS
Paroxysmal Supraventricular Tachycardia
Oregovomab
Carcinoma, Ovarian Epithelial
Efgartigimod
Primary Sjögren's Syndrome
Olorofim
Invasive Fungal Infections
Bedaquiline, pretomanid and TBD09
Drug Susceptible Pulmonary Tuberculosis
PCN-101
Treatment Resistant Depression
NOC-110
Refractory or Unexplained Chronic Cough
J147 Emulsion for Injection
Acute Ischemic Stroke
Futibatinib
Advanced Solid Tumor
Namilumab
Axial Spondyloarthritis
FP-101
Hot Flashes
Propagermanium
Focal Segmental Glomerulosclerosis
BB2603-1
Distal Subungual Onychomycosis
Nirsevimab
RSV Infection
Belantamab mafodotin
Multiple Myeloma
Ixovex-1
Solid Tumor
ER004
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
HBI-8000
Adult T-Cell Lymphoma (ATL)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GSK3196165 (Otilimab) | Phase 3 | Arthritis, Rheumatoid | - | - |
GSK3511294 (Depemokimab) | Phase 3 | Asthma | - | - |
Humira 40 MG in Prefilled Syringe | Phase 3 | Moderate Chronic Plaque Psoriasis | - | - |
Tapinarof | Phase 3 | Plaque Psoriasis | - | - |
Olokizumab 64 mg SC q4w | Phase 3 | Rheumatoid Arthritis | - | - |
Levodopa-Carbidopa Intestinal Gel (LCIG) | Phase 3 | Advanced Parkinson's Disease | - | - |
Tofacitinib 5 mg | Phase 3 | Arthritis, Rheumatoid | - | - |
Recombinant human alpha galactosidase A (agalsidase beta) | Phase 3 | Fabry Disease | - | - |
Benralizumab | Phase 3 | Severe Uncontrolled Asthma | - | - |
Etripamil NS | Phase 3 | Paroxysmal Supraventricular Tachycardia | - | - |
Oregovomab | Phase 3 | Carcinoma, Ovarian Epithelial | - | - |
Efgartigimod | Phase 2 | Primary Sjögren's Syndrome | - | - |
Olorofim | Phase 2 | Invasive Fungal Infections | - | - |
Bedaquiline, pretomanid and TBD09 | Phase 2 | Drug Susceptible Pulmonary Tuberculosis | - | - |
PCN-101 | Phase 2 | Treatment Resistant Depression | - | - |
NOC-110 | Phase 2 | Refractory or Unexplained Chronic Cough | - | - |
J147 Emulsion for Injection | Phase 2 | Acute Ischemic Stroke | - | - |
Futibatinib | Phase 2 | Advanced Solid Tumor | - | - |
Namilumab | Phase 2 | Axial Spondyloarthritis | - | - |
FP-101 | Phase 2 | Hot Flashes | - | - |
Propagermanium | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
BB2603-1 | Phase 2 | Distal Subungual Onychomycosis | - | - |
Nirsevimab | Phase 2 | RSV Infection | - | - |
Belantamab mafodotin | Phase 2 | Multiple Myeloma | - | - |
Ixovex-1 | Phase 2 | Solid Tumor | - | - |
ER004 | Phase 2 | X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) | - | - |
HBI-8000 | Phase 2 | Adult T-Cell Lymphoma (ATL) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in IQVIA HOLDINGS INC.'s drug pipeline?→
CatalystAlert tracks 27 drug candidates in IQVIA HOLDINGS INC.'s (IQV) pipeline across Phase 3, Phase 2. Its lead program is GSK3196165 (Otilimab) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IQVIA HOLDINGS INC.'s next FDA catalyst?→
IQVIA HOLDINGS INC.'s (IQV) next tracked catalyst is a Phase 2 expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IQV biotech catalysts?→
Add IQV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IQVIA HOLDINGS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.